Ponvory 2 mg, 3 mg, 4 mg, 5 mg, 6 mg , 7 mg, 8 mg, 9 mg , 10 mg, 20 mg film-coated tablets

Package leaflet: Information for the patient

Ponvory 2 mg film-coated tablets

Ponvory 3 mg film-coated tablets

Ponvory 4 mg film-coated tablets

Ponvory 5 mg film-coated tablets

Ponvory 6 mg film-coated tablets

Ponvory 7 mg film-coated tablets

Ponvory 8 mg film-coated tablets

Ponvory 9 mg film-coated tablets

Ponvory 10 mg film-coated tablets

Ponvory 20 mg film-coated tablets

ponesimod


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.


What is in this leaflet


1. What Ponvory is and what it is used for

What Ponvory is

Ponvory contains the active substance ponesimod. Ponesimod belongs to a group of medicines called sphingosine-1-phosphate (S1P) receptor modulators.

What Ponvory is used for

Ponvory is used to treat adults with relapsing forms of multiple sclerosis (RMS) with active disease. Active disease in RMS is when there are relapses or when MRI (magnetic resonance imaging) results show signs of inflammation.

What is multiple sclerosis

Multiple sclerosis (MS) affects the nerves in the brain and spinal cord (the central nervous system).

In MS, the immune system (one of the body’s main defence systems) does not work properly. The immune system attacks a protective covering of nerve cells called myelin sheath – this causes inflammation. This breakdown of the myelin sheath (called demyelination) stops the nerves working properly.

Symptoms of MS depend on which part of the brain and spinal cord are affected. These can include problems with walking and balance, weakness, numbness, double vision and blurring, poor coordination and bladder problems.

Symptoms of a relapse may disappear completely when the relapse is over – but some problems may remain.

How Ponvory works

Ponvory reduces circulating lymphocytes, which are white blood cells involved in the immune system. It does this by keeping them in the lymphoid organs (lymph nodes). This means that fewer lymphocytes are available to attack the myelin sheath around the nerves in the brain and spinal cord.

Decreasing nerve damage in patients with MS reduces the number of attacks (relapses) and slows down worsening of the disease.


2. What you need to know before you take Ponvory

Do not take Ponvory if


Warnings and precautions

Talk to your doctor before taking Ponvory if:

If any of the above apply to you (or you are not sure), talk to your doctor before taking Ponvory.


Tell your doctor straight away if you get any of the following side effects while taking Ponvory:

Slow heart rate (bradycardia or bradyarrhythmia)

Ponvory can slow down your heart rate – especially after you take your first dose. You should have an electrocardiogram (ECG, to check your heart’s electrical activity) before you take your first dose of Ponvory or before you restart Ponvory after an interruption in treatment.


Infections

Ponvory can increase your risk of serious infections that can be life-threatening. Ponvory lowers the number of lymphocytes in your blood. These cells fight infection. Their numbers usually return to normal within 1 week of stopping treatment. Your doctor should review a recent blood test of your blood cells before you start taking Ponvory.

Call your doctor straight away if you have any of these symptoms of an infection during treatment with Ponvory or 1 week after your last dose of Ponvory:


Macular oedema

Ponvory can cause a problem with your vision called macular oedema (build-up of fluid in the back of the eye (retina) that may cause changes in vision, including blindness).

The symptoms of macular oedema can be similar to vision symptoms of a MS attack (called optic neuritis). Early on, there may not be any symptoms. Be sure to tell your doctor about any changes in your vision. If macular oedema happens, it usually starts in the first 6 months after you start taking Ponvory.

Your doctor should check your vision before you start taking Ponvory and also anytime you notice vision changes during treatment. Your risk of macular oedema is higher if you have diabetes or have had an inflammation of your eye called uveitis.

Call your doctor straight away if you have any of the following:


Liver problems

Ponvory may cause liver problems. Your doctor should do blood tests to check your liver function before you start taking Ponvory.

Call your doctor straight away if you have any of the following symptoms of liver problems:


Increased blood pressure

As Ponvory can increase your blood pressure, your doctor should check your blood pressure regularly during treatment with Ponvory.


Exposure to the sun and protection against the sun

As Ponvory may increase the risk of skin cancer, you should limit your exposure to sunlight and UV (ultraviolet) light, by:


Breathing problems

Some people who take Ponvory have shortness of breath. Call your doctor straight away if you have new or worsening breathing problems.


Swelling and narrowing of the blood vessels in your brain

A condition called PRES (posterior reversible encephalopathy syndrome) has happened with medicines acting similarly to Ponvory. Symptoms of PRES usually improve when you stop taking Ponvory. However, if left untreated, it may lead to a stroke.

Call your doctor straight away if you have any of the following symptoms:


Worsening of multiple sclerosis after stopping Ponvory

When Ponvory is stopped, symptoms of MS may return. They may be worse compared to before or during treatment. Always talk to your doctor before you stop taking Ponvory. Tell your doctor if you have worsening symptoms of MS after stopping Ponvory.

Children and adolescents

Ponvory has not been studied in children and adolescents, therefore it is not recommended for use in children and adolescents aged less than 18 years.

Other medicines and Ponvory

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. Especially tell your doctor if you take:


Vaccines and Ponvory

Tell your doctor if you have recently received any vaccinations or if you are planning to receive a vaccination. You should avoid receiving live vaccines during treatment with Ponvory. If you receive a live vaccine, you may get the infection the vaccine was meant to prevent. Ponvory should be stopped 1 week before and for 4 weeks after receiving a live vaccine. Also, other vaccines may not work as well when given during treatment with Ponvory.


Pregnancy, contraception, and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.

Pregnancy


Women of childbearing potential/Contraception in females

If you are a woman of childbearing potential:

Talk to your doctor about reliable methods of contraception.

If you do become pregnant while taking Ponvory, stop taking Ponvory and tell your doctor straight away.

If you become pregnant within 1 week after you stop taking Ponvory, talk to your doctor.

Breast-feeding

You should not breast-feed while you are taking Ponvory. This is to avoid a risk of side effects for the baby since Ponvory may pass into breast milk.

Driving and using machines

Ponvory is not expected to have an influence on your ability to drive and use machines.

Ponvory contains lactose

This medicine contains lactose which is a type of sugar. If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.

Ponvory contains sodium

This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.


3. How to take Ponvory

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

How to take


Treatment initiation pack (14-day)


Treatment initiation pack day - Daily dose

Day 1 - 2 mg

Day 2 - 2 mg

Day 3 - 3 mg

Day 4 - 3 mg

Day 5 - 4 mg

Day 6 - 4 mg

Day 7 - 5 mg

Day 8 - 6 mg

Day 9 - 7 mg

Day 10 - 8 mg

Day 11 - 9 mg

Day 12 - 10 mg

Day 13 - 10 mg

Day 14 - 10 mg


Maintenance dose


If you take more Ponvory than you should

If you have taken more Ponvory than you should, call your doctor straight away or go to a hospital straight away. Take the medicine pack and this package leaflet with you.


If you forget to take Ponvory

Do not take a double dose to make up for a forgotten tablet.

Write down the date you start taking the medicine so you will know if you miss 4 or more doses in a row.


Do not stop taking Ponvory without talking with your doctor first.

Do not restart Ponvory after stopping it for 4 or more days in a row without seeking advice from your doctor. You will need to restart your treatment with a new treatment initiation pack.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.


4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Some side effects could be or could become serious

Tell your doctor or pharmacist immediately if you notice any of the side effects listed below because they may be signs of serious effects:

Common (may affect up to 1 in 10 people)


Uncommon (may affect up to 1 in 100 people)


Other side effects

Very common (may affect more than 1 in 10 people)


Common (may affect up to 1 in 10 people)


Uncommon (may affect up to 1 in 100 people)


Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via HPRA Pharmacovigilance, website: www.hpra.ie. By reporting side effects you can help provide more information on the safety of this medicine.


5. How to store Ponvory

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister foil after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


6. Contents of the pack and other information

What Ponvory contains

Tablet core

Croscarmellose sodium, lactose monohydrate (see “Ponvory contains lactose”), magnesium stearate, microcrystalline cellulose, Povidone K30, silica colloidal anhydrous and sodium laurilsulfate.

Tablet coating

Hypromellose 2910, lactose monohydrate, Macrogol 3350, titanium dioxide and triacetin.

Ponvory 3 mg film-coated tablets

Iron oxide red (E172) and iron oxide yellow (E172)

Ponvory 4 mg film-coated tablets

Iron oxide red (E172) and black iron oxide (E172)

Ponvory 5 mg film-coated tablets

Black iron oxide (E172) and iron oxide yellow (E172)

Ponvory 7 mg film-coated tablets

Iron oxide red (E172) and iron oxide yellow (E172)

Ponvory 8 mg film-coated tablets

Iron oxide red (E172) and black iron oxide (E172)

Ponvory 9 mg film-coated tablets

Iron oxide red (E172) and black iron oxide (E172), iron oxide yellow (E172)

Ponvory 10 mg film-coated tablets

Iron oxide red (E172) and iron oxide yellow (E172)

Ponvory 20 mg film-coated tablets

Iron oxide yellow (E172)


What Ponvory looks like and contents of the pack

Ponvory 2 mg film-coated tablets are white, round, biconvex, film-coated tablet of 5 mm diameter with “2” on one side and an arch on the other side.

Ponvory 3 mg film-coated tablets are red, round, biconvex, film-coated tablet of 5 mm diameter with “3” on one side and an arch on the other side.

Ponvory 4 mg film-coated tablets are purple, round, biconvex, film-coated tablet of 5 mm diameter with “4” on one side and an arch on the other side.

Ponvory 5 mg film-coated tablets are green, round, biconvex, film-coated tablet of 8.6 mm diameter with “5” on one side and an arch and an “A” on the other side.

Ponvory 6 mg film-coated tablets are white, round, biconvex, film-coated tablet of 8.6 mm diameter with “6” on one side and an arch and an “A” on the other side.

Ponvory 7 mg film-coated tablets are red, round, biconvex, film-coated tablet of 8.6 mm diameter with “7” on one side and an arch and an “A” on the other side.

Ponvory 8 mg film-coated tablets are purple, round, biconvex, film-coated tablet of 8.6 mm diameter with “8” on one side and an arch and an “A” on the other side.

Ponvory 9 mg film-coated tablets are brown, round, biconvex, film-coated tablet of 8.6 mm diameter with “9” on one side and an arch and an “A” on the other side.

Ponvory 10 mg film-coated tablets are orange, round, biconvex, film-coated tablet of 8.6 mm diameter with “10” on one side and an arch and an “A” on the other side.

Ponvory 20 mg film-coated tablets are yellow, round, biconvex, film-coated tablet of 8.6 mm diameter with “20” on one side and an arch and an “A” on the other side.


Ponvory treatment initiation pack (wallet configuration)

Each blister pack of 14 film-coated tablets for a 2-week treatment schedule contains:

2 film-coated tablets of 2 mg

2 film-coated tablets of 3 mg

2 film-coated tablets of 4 mg

1 film-coated tablet of 5 mg

1 film-coated tablet of 6 mg

1 film-coated tablet of 7 mg

1 film-coated tablet of 8 mg

1 film-coated tablet of 9 mg

3 film-coated tablets of 10 mg


Ponvory 20 mg film-coated tablets (maintenance pack) (wallet configuration)

Pack containing 28 film-coated tablets for a 4-week treatment schedule or in a multipack containing 84 (3 packs of 28) film-coated tablets for a 12-week treatment schedule.

Not all pack sizes may be marketed in your country.


Marketing Authorisation Holder

LABORATOIRES JUVISE PHARMACEUTICALS

149 Boulevard Bataille de Stalingrad

69100 Villeurbanne

France


Manufacturer

Janssen Pharmaceutica NV

Turnhoutseweg 30

B-2340 Beerse

Belgium


Patheon France

40 Boulevard De Champaret

38300 Bourgoin Jallieu

France


This leaflet was last revised in February 2026.

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency web site: https://www.ema.europa.eu